Related Experiment Video
Updated: Aug 10, 2026

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat
Published on: June 4, 2012
Vancomycin-Resistant Enterococcus: Infectious Endocarditis Treatment
1The Anti-Infective Research Laboratory, Department of Pharmacy Services, Detroit Receiving Hospital and University Health Center, 4201 St. Antoine Blvd, Detroit, MI 48201, USA.
Abstract:
Vancomycin-resistant Enterococcus species represent serious gram-positive pathogens for which there is currently no recommended therapy. There are a number of new antibiotics with activity against these pathogens in development. Although there is a great deal of experience with some of these agents for skin and soft tissue infections, bacteremia, pneumonia, and intra-abdominal infections, there is currently little information available for the treatment of endocarditis. Animal and limited human data thus far suggest that new agents such as quinuprisitin-dalfopristin, LY333328 (a new glycopeptide antibiotic), and daptomycin (a lipopeptide antibiotic) may prove useful for this indication. Additional information, and especially combination treatment, are warranted to improve success and limit the emergence of resistance to these new antibiotics.
Insights
Vancomycin-resistant Enterococcus infections are a serious threat with limited treatment options. New antibiotics like daptomycin show promise for endocarditis, but more research, especially on combination therapies, is crucial.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Vancomycin-resistant Enterococcus (VRE) species are critical gram-positive pathogens.
- Currently, no definitive therapy is recommended for VRE infections.
- Emerging antibiotic resistance necessitates novel treatment strategies.
Purpose of the Study:
- To review the current landscape of antibiotics for VRE infections.
- To evaluate the potential of new antimicrobial agents for treating VRE endocarditis.
- To highlight the need for further research into combination therapies.
Main Methods:
- Review of existing literature on VRE treatment.
- Analysis of preclinical (animal) and clinical data for novel agents.
- Assessment of antibiotic efficacy for various VRE infection types.
Main Results:
- New agents including quinupristin-dalfopristin, LY333328, and daptomycin demonstrate activity against VRE.
- Limited data suggest potential utility of these agents for VRE endocarditis.
- Experience with these agents is extensive for other infections but limited for endocarditis.
Conclusions:
- Quinupristin-dalfopristin, LY333328, and daptomycin may offer therapeutic options for VRE endocarditis.
- Further investigation is required to establish optimal treatment regimens.
- Combination therapies are essential to enhance efficacy and mitigate resistance development.
Related Concept Videos
Endocarditis I: Introduction
Endocarditis III: Medical Management
Endocarditis IV: Nursing Management
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
Cardiomyopathy V: Interprofessional Care

